Recent Study: EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022

From: Fast Market Research, Inc.
Published: Mon Apr 29 2013

EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022


The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors. Estrogen is needed for the health of these tissues and structures, a lack of which causes them to undergo atrophy (Castelo-Branco and Rostro, 2007; Nappi and Kokot-Kierepa, 2012). During the menopause transition and postmenopausal periods, women can experience a number of symptoms primarily due to estrogen depletion that include vasomotor and urogenital symptoms. Although vasomotor symptoms typically resolve over time, urogenital symptoms remain a persistent consequence of estrogen depletion (Winneker and Harris, 2011). Postmenopausal vaginal atrophy (PVA) is the term used to describe the group of urogenital symptoms that arise due to estrogen depletion and is also known as urogenital atrophy, vulvovaginal atrophy, and atrophic vaginitis (Mac Bride et al., 2010; Willhite and O'Connell, 2001). Approximately 10%-50% of postmenopausal women experience symptoms of vaginal atrophy, but only about 25% of them seek medical treatment (NAMS, 2007; Nappi and Kokot-Kierepa, 2012).

Full Report Details at

Cultural and social attitudes toward sexuality and aging are the primary determinants of the extent to which women report symptoms associated with PVA; therefore, the amount of PVA epidemiology data available in a given country varies considerably (Barlow et al., 1997). Today, women are living longer and spend approximately one third of their lives in the postmenopausal state. For this reason, there is evidence that in some regions, such as North America, attitudes towards the menopause transition are changing, and women are becoming more vocal about their menopause experience (Wright, 1998). Any changes in cultural and social norms that decrease the stigma surrounding menopause will likely lead to an increase in the diagnosed prevalence of PVA over time. The increase could exceed the projections of PVA prevalence found in this analysis.


* The Postmenopausal Vaginal Atrophy EpiCast Report provides an overview of the risk factors and global trends of postmenopausal vaginal atrophy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan).
* It includes a 10-year epidemiology forecast of PVA prevalent cases segmented by age (in five-year increments beginning at 50 years and ending at 79 years) and severity (mild, moderate, and severe) in the 7MM.

Reasons to buy

* Develop business strategies by understanding the trends shaping and driving the global postmenopausal vaginal atrophy market.
* Quantify patient populations in the global postmenopausal vaginal atrophy market to improve product design, pricing, and launch plans.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »